What do systematic reviews say?

Continuous positive airway pressure (CPAP) vs phosphodiesterase type 5 inhibitors

• Non‐invasive positive airway pressure therapy for improving erectile dysfunction in men with obstructive sleep apnoea 2021 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 152 participants
  Low

Continuous positive airway pressure (CPAP) vs phosphodiesterase type 5 inhibitors

• Non‐invasive positive airway pressure therapy for improving erectile dysfunction in men with obstructive sleep apnoea 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 40 participants
  Very low

Continuous positive airway pressure (CPAP) vs phosphodiesterase type 5 inhibitors

• Non‐invasive positive airway pressure therapy for improving erectile dysfunction in men with obstructive sleep apnoea 2021 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 122 participants
  Very low

Continuous positive airway pressure (CPAP) vs phosphodiesterase type 5 inhibitors

The review found no eligible studies for this question.

• Non‐invasive positive airway pressure therapy for improving erectile dysfunction in men with obstructive sleep apnoea 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Continuous positive airway pressure (CPAP) vs phosphodiesterase type 5 inhibitors

It is very uncertain whether continuous positive airway pressure (CPAP) changes minor adverse events compared with phosphodiesterase type 5 inhibitors (very low certainty).

• Non‐invasive positive airway pressure therapy for improving erectile dysfunction in men with obstructive sleep apnoea 2021 · Cochrane Headline outcomes only
  RR 1.33 [0.34, 5.21]
  1 study · 40 participants
  Very low